Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
Authors:
Open Access
- 1 November 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (11) , e1916091
Abstract
Erdafitinib was recently granted accelerated approval by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic urothelial cancer with fibroblast growth factor receptor 2 (FGFR2) or FGFR3 gene mutations or fusions.1 Erdafitinib targets FGFR2 and FGFR3, receptors commonly expressed in metastatic urothelial cancer, and belongs to the more general class of tyrosine kinase inhibitors.2 It was the first FGFR-targeting drug approved by the FDA. The approval of erdafitinib was based on overall response rate (ORR) in 87 patients with FGFR2 and FGFR3 alterations from a single-group, phase 2, multicenter study.2,3 Among responders, median (interquartile range) duration of response was found to be 5.4 (4.2-6.9) months. The response rate varied considerably by alteration, with an ORR of 40.6% (26 of 64) for FGFR3 point mutations, 11.1% (2 of 18) for FGFR3 fusions, and 0% (0 of 6) for FGFR2 fusions.3Keywords
This publication has 45 references indexed in Scilit:
- A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group StudyGynecologic Oncology, 2014
- Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsAnnals of Oncology, 2014
- Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell CancerClinical Cancer Research, 2014
- Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast CancerClinical Cancer Research, 2013
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell CarcinomaClinical Cancer Research, 2013
- Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiformeJournal of Neuro-Oncology, 2012
- A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258), an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors, in Patients with Advanced MelanomaClinical Cancer Research, 2011
- FGFR inhibitor induced peripheral neuropathy in patients with advanced RCCAnnals of Oncology, 2010
- Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic AgentsChest, 1989